Ph1-negative chronic myeloproliferative neoplasms (MPN), immune thrombocytopenic purpura (ITP), and thrombotic thrombocytopenic purpura (PTT)

Research area

The group is actively working in collaboration with national and international clinics to investigate the effectiveness and the best ways of using the latest generation of drugs for treating MPNs, ITP, and PPT. Between 2018 and 2021, 40 studies on MPN and 10 on ITP were initiated (some of which are still ongoing).

In addition, the group continues to coordinate many clinical studies across a national network composed of numerous hematological centers. Many of these studies, on MPN and ITP, have become scientific publications.

Research project

Currently, in addition to clinical experimental drug studies which are ongoing or in the planning phase,there are also studies in the development and implementation phase which are assessing the impact of SARS-CoV-2 on the clinical course of these diseases.

Dr. Nicola Vianelli is on the national board of GIMEMA for ITP research, while Dr. Francesca Palandri is on the board dedicated to MPNs. Both of them, at the invitation of SIE and ISS, are on national boards working to draw up the guidelines for MPNs and ITP. Dr. Vianelli has also acted as external reviewer for the guidelines on PTT. Together they are part of the national scientific board which consults for the ‘associazione italiana pazienti affetti da Piastrinopenia Immune’ (AIPIT).

Collaborators

Christian Di Pietro, specializzando.

Emanuele Sutto, specializzando.

Camilla Mazzoni, specializzanda.